- KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
- Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
- Kazia announces presentation of new data at AACR Annual Meeting
- Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
Key statistics
On Friday, Kazia Therapeutics Ltd (KZIA:NAQ) closed at 0.272, 45.77% above the 52 week low of 0.1866 set on Mar 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.299 |
---|---|
High | 0.31 |
Low | 0.265 |
Bid | 0.271 |
Offer | 0.288 |
Previous close | 0.2825 |
Average volume | 223.65k |
---|---|
Shares outstanding | 13.18m |
Free float | 777.07k |
P/E (TTM) | -- |
Market cap | 7.17m USD |
EPS (TTM) | -0.8203 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼